MyBioSource

ELISA/assay

Rat Plasminogen ELISA Kit

MBS564124

1 x96 Wells

470 USD

MBS564124

ELISA Kit

Rat Plasminogen ELISA Kit

Plasminogen

Rat Plasminogen

plasminogen; Plasminogen; plasminogen; OTTHUMP00000017544; OTTHUMP00000017545; OTTHUMP00000197002; plasminogen; N/A

PLG; PLG; DKFZp779M0222; N/A

PLMN_HUMAN

Rat

Store at 4 degree C.

Samples: Immunoperoxidase Assay for Determination of Plasminogen in Rat Samples. Intended Uses: The Plasminogen test kit is a highly sensitive two-site enzyme linked immunoassay (ELISA) for measuring Plasminogen in biological samples of rats.

ELISA Kit

Principle of the Assay: The principle of the double antibody sandwich ELISA is represented in Figure 1. In this assay the Plasminogen present in samples reacts with the anti-Plasminogen antibodies which have been adsorbed to the surface of polystyrene microtitre wells. After the removal of unbound proteins by washing, anti-PMG antibodies conjugated with horseradish peroxidase (HRP), are added. These enzyme-labeled antibodies form complexes with the previously bound PMG. Following another washing step, the enzyme bound to the immunosorbent is assayed by the addition of a chromogenic substrate, 3,3',5,5'-tetramethylbenzidine (TMB). The quantity of bound enzyme varies directly with the concentration of PMG in the sample tested; thus, the absorbance, at 450 nm, is a measure of the concentration of PMG in the test sample. The quantity of PMG in the test sample can be interpolated from the standard curve constructed from the standards, and corrected for sample dilution. Background: Plasminogen (PMG) is a glycoprotein produced by the liver. It is the precursor for plasmin, which targets fibrin in the process of dissolution of fibrin blood clots. Plasminogen is present in plasma and most extravascular fluids. The important role of plasminogen in fibrinolytic system makes it an interesting marker for various diseases.

190026

P00747

90,569 Da

Angiopoietin Receptor Tie2-mediated Signaling Pathway 137917!!Blood Clotting Cascade Pathway 198840!!Complement And Coagulation Cascades Pathway 198880!!Complement And Coagulation Cascades Pathway 83073!!Complement And Coagulation Cascades Pathway 484!!Diabetes Pathways 105902!!Dissolution Of Fibrin Clot Pathway 106061!!Formation Of Platelet Plug Pathway 106029!!Hemostasis Pathway 106028!!Influenza A Pathway 217173

The protein encoded by this gene is a secreted blood zymogen that is activated by proteolysis and converted to plasmin and angiostatin. Plasmin dissolves fibrin in blood clots and is an important protease in many other cellular processes while angiostatin inhibits angiogenesis. Defects in this gene are likely a cause of thrombophilia and ligneous conjunctivitis. Two transcript variants encoding different isoforms have been found for this gene.

Function: Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Ref.26Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo. Ref.26. Catalytic activity: Preferential cleavage: Lys- -Xaa > Arg- -Xaa; higher selectivity than trypsin. Converts fibrin into soluble products. Ref.29. Enzyme regulation: Converted into plasmin by plasminogen activators, both plasminogen and its activator being bound to fibrin. Activated with catalytic amounts of streptokinase. Plasmin activity inhibited by SERPINE2. Ref.26. Subunit structure: Interacts (both mature PLG and the angiostatin peptide) with CSPG4 and AMOT. Interacts (via the Kringle domains) with HRG; the interaction tethers PLG to the cell surface and enhances its activation. By similarity. Ref.19 Ref.24 Ref.25 Ref.27 Ref.30. Subcellular location: Secreted. Note: Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface. Ref.24 Ref.26. Tissue specificity: Present in plasma and many other extracellular fluids. It is synthesized in the liver. Domain: Kringle domains mediate interaction with CSPG4. Ref.25. Post-translational modification: N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide. Involvement in disease: Defects in PLG are a cause of susceptibility to thrombosis (THR) [. MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation. Ref.48 Ref.51 Ref.52 Ref.53Defects in PLG are the cause of plasminogen deficiency (PLGD) [. MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa. Ref.48 Ref.50 Ref.51 Ref.52 Ref.53 Ref.54 Ref.55 Ref.56. Miscellaneous: Plasmin is inactivated by alpha-2-antiplasmin immediately after dissociation from the clot. Sequence similarities: Belongs to the peptidase S1 family. Plasminogen subfamily.Contains 5 kringle domains.Contains 1 PAN domain.Contains 1 peptidase S1 domain.

1 x96 Wells

470 USD